Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study
Open Access
- 10 August 2023
- journal article
- editorial
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 189 (6) , 685-694
Abstract
Background: Sleep disturbance is a prominent symptom of atopic dermatitis (AD) and can result in insomnia, daytime fatigue, drowsiness, reduced productivity and impaired quality of life (QoL). Objectives: The Dupilumab Effect on Sleep in AD Patients (DUPISTAD) phase IV randomized double-blinded placebo-controlled study evaluated the impact of dupilumab treatment on sleep and other patient- and physician-reported outcomes. Methods: Adults with moderate-to-severe AD were randomized 2 : 1 to dupilumab 300 mg once every 2 weeks (q2w) or placebo for 12 weeks; concomitant topical corticosteroids were permitted. Patients subsequently entered an open-label phase and received dupilumab 300 mg q2w for a further 12 weeks. The primary endpoint was the percentage change in sleep quality from baseline to week 12, assessed using a novel numeric rating scale (NRS). Secondary and exploratory endpoints included percentage change in peak pruritus NRS (PP NRS), change in SCORing Atopic Dermatitis (SCORAD), SCORAD sleep visual analogue scale (VAS), Eczema Area and Severity Index, Patient-Reported Outcomes Measurement Information System (PROMIS) sleep-related impairment T-score and the Epworth Sleepiness Scale. Sleep diary and wrist actigraphy measurements were recorded throughout the study. Results: In total, 127 patients received dupilumab and 61 patients received placebo. Demographic and baseline disease characteristics were balanced between groups. Sleep quality NRS significantly improved in patients treated with dupilumab by week 12 vs. placebo [least squares mean of the difference (LSMD) −15.5%, P < 0.001]. PP NRS (LSMD −27.9%, P < 0.001), SCORAD (LSMD −15.1, P < 0.001), SCORAD sleep VAS (LSMD −2.1, P < 0.001) and PROMIS T-score (LSMD −3.6, P < 0.001) were also significantly improved at week 12 with dupilumab vs. placebo. The overall percentage of patients reporting treatment-emergent adverse events was lower in the dupilumab group (56.7%) than in the placebo group (67.2%). Conclusions: Dupilumab significantly improved sleep quality and perception of sleep continuity, itch, metrics of AD severity and QoL in adults with moderate-to-severe AD, with an acceptable safety profile compared with placebo.Keywords
Funding Information
- Sanofi and Regeneron Pharmaceuticals Inc
This publication has 35 references indexed in Scilit:
- Atopic dermatitisThe Lancet, 2016
- Sleep Disturbances in Adults with Eczema Are Associated with Impaired Overall Health: A US Population-Based StudyJournal of Investigative Dermatology, 2015
- Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal miceProceedings of the National Academy of Sciences, 2014
- Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genesProceedings of the National Academy of Sciences, 2014
- EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important differenceAllergy, 2011
- Wrist ActigraphyChest, 2011
- Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in EuropeAllergy, 2011
- The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008Journal of Clinical Epidemiology, 2010
- The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical resultsBritish Journal of Dermatology, 2008
- The eczema area and severity index (EASI): assessment of reliability in atopic dermatitisExperimental Dermatology, 2001